Key MessagesUsing metrics proposed by the Joint United Nations Programme on AIDS (UNAIDS), we evaluate progress toward HIV epidemic control in a severely affected South African setting. Between 2005 and 2017, we tested 39 735 participants (aged 15--49 years) for HIV and followed 22 758 HIV-negative and 13 460 HIV-positive participants from a large population-based cohort in rural KwaZulu-Natal.For the first time, we use data from a population-based cohort to estimate the percentage reduction in incidence, the absolute incidence rate, the incidence-mortality ratio and the incidence-prevalence ratio. Our results, which are derived from empirical data rather than mathematical models, show remarkable heterogeneity in the four metrics over place and time.There has been impressive progress toward HIV epidemic control in this hyperendemic South African setting. Nevertheless, expanded and sustained prevention services are needed to reach key UNAIDS milestones. Our results highlight geographical areas that could benefit from these prevention services.

Introduction
============

In 2014, the Joint United Nations Programme on AIDS (UNAIDS) announced a set of ambitious but achievable targets to end the HIV epidemic by 2030.[@dyz269-B1] To assess interim progress, a scientific panel recently convened in Glion, Switzerland, to build consensus around the measurement of epidemic control, defined as a reduction of disease incidence, prevalence or mortality in a geographical area to a locally acceptable level.[@dyz269-B2]^,^[@dyz269-B3] The panel proposed four metrics called the percentage reduction in incidence, the absolute incidence rate, the incidence-prevalence ratio and the incidence-mortality ratio, each having a target to galvanize political support and promote real-world impact in the fight against HIV.

Progress toward HIV epidemic control has generally been measured through reductions in the number of new infections and/or declines in the absolute incidence rate.[@dyz269-B4] The incidence-prevalence ratio, defined as the number of new infections occurring over the lifetime of an infected person on treatment, has also been used, but less frequently and in high-income countries.[@dyz269-B10] Empirical estimates are currently unavailable for the incidence-mortality ratio, which measures the number of new infections relative to the number of all-cause HIV-related deaths.[@dyz269-B13] Using a modelling approach, the UNAIDS recently estimated the four metrics[@dyz269-B14] and Galvani *et al*.[@dyz269-B15] assessed their strengths and weaknesses; Ghys *et al.*[@dyz269-B16] also provided a conceptual overview. To date, however, the four metrics have not been estimated from empirical data to evaluate the state of the HIV epidemic at the population level.

In this study, we present temporal and geospatial estimates of the four epidemic metrics from South Africa, the country most affected by the HIV pandemic.[@dyz269-B4] South Africa is of considerable interest, having received substantial domestic and foreign investment to scale up the world's largest HIV treatment programme.[@dyz269-B4]^,^[@dyz269-B17] To evaluate progress toward epidemic control, we tested 39 735 participants (aged 15--49 years) for HIV, and followed a cohort of 22 758 HIV-negative and 13 460 HIV-positive participants from a hyperendemic setting in rural KwaZulu-Natal.

Methods
=======

Data collection
---------------

The Africa Health Research Institute (AHRI) maintains a comprehensive demographic surveillance system in the sub-district of Hlabisa. The surveillance area is 438 km^2^ in size and home to approximately 90 000 residents and 11 000 households. Households are mostly scattered across the predominantly rural landscape, with several peri-urban settlements and a single urban township.

Twice yearly, trained fieldworkers visit all households in the surveillance area to interview a key informant. The household head or the most senior household member is often the key informant; if not available, other suitable household members are selected. The key informant provides information on: the physical attributes of the household; the resident members and their relationship to one another; members who join, leave or die; and the migration patterns of members, including place of origin and destination. For each death in the household, the key informant completes a detailed verbal autopsy questionnaire administered by the fieldworker. Household response rates are typically *\>*95%.[@dyz269-B18]

Nested within the household surveillance survey is an annual HIV survey that has been ongoing since 2004. All persons who reside in the surveillance area and are older than 15 years are eligible for HIV testing. After obtaining written consent, the fieldworkers interview participants and extract blood according to the *UNAIDS and WHO Guidelines for Using HIV Testing Technologies in Surveillance*.[@dyz269-B19] The dried blood spots are transported to the AHRI laboratory in Durban where HIV status is determined by antibody testing with a broad-based HIV-1/HIV-2 enzyme-linked immunosorbent assay (ELISA) (Vironostika HIV-1 Microelisa System: Biomérieux, Durham, NC, USA) followed by a second ELISA (Wellcozyme HIV1 + 2 GACELISA: Murex Diagnostics Benelux B.V., Breukelen, The Netherlands).

Antiretroviral therapy (ART) services have been freely available at 17 public health care clinics within or adjacent to the surveillance area since 2004, with a CD4+ T cell count eligibility criterion of *\<*200 cells/µL. All patients with CD4+ T cell counts *\<*350 cells/µL became eligible for ART in 2011. In 2015, ART was made available to HIV-positive pregnant women regardless of CD4+ T cell count, and to all late adolescents and adults with CD4+ T cell counts *\<*500 cells/µL. CD4+ eligibility criteria were removed in September 2016.[@dyz269-B20] AHRI has linked ART usage data collected at the health care clinics to the surveillance database.

Metrics
-------

We calculated the percentage reduction in new infections, the absolute incidence rate, the incidence-mortality ratio and the incidence-prevalence ratio for men and women aged 15--49 years. Detailed notation is provided in the Methods section of the Supplement, available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online. We define $N_{y}^{T}$ as the total number of participants (irrespective of HIV testing status) who were residents in the surveillance area for \>50% of the *y*th year (*y *=* *2005,$~\ldots~$*,* 2017). Since all measures are calculated by year, we drop the *y* subscript for convenience. Let *N* denote the number of participants who tested for HIV. From the *N* participants, we calculated the HIV-positive prevalence (*H*^+^) and the HIV-negative prevalence (*H^−^*) as proportions. Further, let *E*^+^ denote the expected number of HIV-positive participants, where $E^{+} = N^{T} \times H^{+},$ and let *E^−^* denote the expected number of HIV-negative participants, where $E^{-} = N^{T} \times H^{-}.~$ We use these measures to derive the four epidemic control metrics.

To calculate the absolute incidence rate, we identified all participants with a first HIV-negative result followed by at least one valid HIV test result during the observation period. We recorded the exposure time and the number of repeat-testers who converted from an HIV-negative to an HIV-positive result. We then calculated the incidence rate per 100 person-years, denoted by *IR*, using methods described elsewhere.[@dyz269-B21] A well-cited target for epidemic control is to decrease the absolute incidence rate to less than one new HIV event per 1000 uninfected adults or person-years.[@dyz269-B22]^,^[@dyz269-B23] To calculate the expected number of new infections, we multiplied the absolute incidence rate by the expected number of HIV-negative participants: *I* = *IR × E^−^*. We used this result to obtain the percentage change in the expected number of new infections over a given time period, defined as $I\% = \left( {I_{y2} - I_{y1}} \right)/I_{y1} \times 100$, where the subscripts $y_{1}$ and $y_{2}$ denote an earlier and later year, respectively. Targets for percentage reductions will vary by country and scale of the local epidemic. The UNAIDS, for example, aims to reduce the global number of new HIV infections by 75% between 2010 and 2020.[@dyz269-B1]

To obtain the incidence-mortality ratio, we followed all HIV-positive participants and recorded the survival time and number of all-cause related deaths. We denote the HIV mortality rate by *M.* Next, we calculated the expected number of deaths, *D*, by multiplying the HIV-related mortality rate by the expected number of HIV-positive participants: $D = M \times E^{+}.$ The incidence-mortality ratio is given as *IMR* = $I/D$ with an epidemic control threshold \<1, which is achieved when the number of new HIV infections (numerator) falls below the number of all-cause HIV-related deaths (denominator) in a given year.[@dyz269-B13]

For the incidence-prevalence ratio, we divided the expected number of new HIV-infected participants by the expected number of opposite-sex HIV-positive participants, such that the *IPR* = $I/E^{+}$. The *IPR* threshold for epidemic control is \<0.03, which assumes that the average survival time of a newly infected person on ART is 33 years. To achieve epidemic control, fewer than one new infection should occur over the 33-year-period, which translates into 1/33 or three new infections per 100 people living with HIV per year.[@dyz269-B2]^,^[@dyz269-B16] Because of the generalized, heterosexual epidemic in sub-Saharan Africa, we used opposite-sex versions of the incidence-prevalence ratio, since new male infections are largely related to the number of HIV-positive females and vice versa.

Using the same methodology as above, we computed geospatial versions of the four epidemic control metrics. To do this, we used a moving two-dimensional Gaussian kernel of 3-km search radius,[@dyz269-B24] the size of which was determined from previous work.[@dyz269-B25] We identified the household coordinates of all participants and superimposed the expected number of new HIV infections and the expected number of AIDS-related deaths on a geographical representation of the study area consisting of a grid of 1 km x 1 km pixels. For each year, we calculated Gaussian weighted estimates of the above measures and generated a raster grid for each. Next, we calculated *I* by multiplying the raster grids of *IR*, *H^−^* and *N^T^*. We calculated the incidence-mortality ratio by dividing the raster grid of *I* by the raster grid of *D*, and used a similar procedure for the opposite-sex incidence-prevalence ratio. We undertook all statistical computations using R version 3.6.2, and all raster grid computations using map algebra in ArcGIS version 10.5.[@dyz269-B26]

Ethical approval
----------------

Ethics approval for data collection and use was obtained from the biomedical and ethics committee (BREC) of the University of KwaZulu-Natal (Durban, South Africa), BREC approval number BE290/16.

Results
=======

[Table 1](#dyz269-T1){ref-type="table"} shows the number of participants who tested in the HIV survey by year. A detailed description of the HIV participation rates is provided elsewhere.[@dyz269-B6] The mean age of the HIV testers was 27 \[interquartile range (IQR): 18--35\] years and approximately 60% of these participants were women. Between 2005 and 2017, the percentage of participants who tested at least once for HIV increased from 42% to 79%. During this period, ART coverage increased from 2% to 45%.

###### 

Particiation rates for all persons (aged 15--49 years) in the HIV surveillance survey, the HIV incidence cohort and the HIV mortality cohort

         HIV survey[^a^](#tblfn1){ref-type="table-fn"}   HIV incidence cohort[^b^](#tblfn2){ref-type="table-fn"}   HIV mortality cohort[^c^](#tblfn3){ref-type="table-fn"}                                     
  ------ ----------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- -------- --------------- -------- -------------
  2005   9363 (60.1)                                     42.5                                                      2.0                                                       13 212   9697 (73.4)     3940     3704 (94.0)
  2006   8212 (61.3)                                     51.5                                                      5.1                                                       15 453   11 240 (72.7)   4696     4194 (89.3)
  2007   7161 (63.4)                                     53.8                                                      9.8                                                       17 271   12 514 (72.5)   5441     4661 (85.7)
  2008   7203 (62.7)                                     56.4                                                      14.2                                                      19 009   13 732 (72.2)   6167     5044 (81.8)
  2009   6215 (64.4)                                     61.9                                                      18.7                                                      20 003   14 352 (71.8)   6818     5377 (78.9)
  2010   7978 (65.3)                                     64.7                                                      23.4                                                      22 276   15 842 (71.1)   7829     6021 (76.9)
  2011   7219 (64.3)                                     67.8                                                      28.7                                                      23 747   16 684 (70.3)   8564     6403 (74.8)
  2012   5430 (64.5)                                     67.2                                                      33.7                                                      25 172   17 616 (70.0)   9137     6631 (72.6)
  2013   6902 (64.9)                                     70.4                                                      37.4                                                      27 101   18 877 (69.7)   9934     7028 (70.7)
  2014   6473 (66.0)                                     72.2                                                      40.6                                                      28 578   19 912 (69.7)   10 670   7382 (69.2)
  2015   9115 (66.4)                                     76.3                                                      45.3                                                      30 621   21 185 (69.2)   11 665   7993 (68.5)
  2016   10 348 (67.7)                                   79.0                                                      46.0                                                      32 880   22 271 (67.7)   12 794   8665 (67.7)
  2017   7609 (66.3)                                     79.3                                                      44.9                                                      34 232   22 758 (66.5)   13 460   8736 (64.9)

Shows the number of participants who tested for HIV and the percentage who were women. Ever tested represents the percentage of participants who tested at least once for HIV. ART coverage is the percentage of HIV-positive participants on treatment.

Shows the number and percentage of eligible HIV-negative participants who entered into the HIV incidence cohort. Participants must have had a first HIV-negative test follwed by at least one HIV test result.

Shows the number and percentage of eligible HIV-positive participants who entered into the HIV mortality cohort.

Of the eligible HIV-negative participants, 71% (minimum--maximum range: 66--73%) entered the HIV incidence cohort and contributed person-time to the analysis ([Table 1](#dyz269-T1){ref-type="table"}). Among the 22 758 participants in the HIV-negative cohort, we observed 3420 seroconversions over 96 303 person-years of follow-up, with an overall incidence rate of 3.53 seroconversions per 100 person-years. Of the eligible HIV-positive participants, 77% (minimum--maximum range: 65--94%) entered the HIV mortality cohort and contributed person-time to the analysis. For the HIV mortality cohort, we observed 1672 deaths over 74 749 person-years of follow-up, with a mortality rate of 2.24 deaths per 100 person-years.

The summary statistics used to calculate the epidemic metrics for all participants are shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online. [Table 2](#dyz269-T2){ref-type="table"} shows these results by sex. The first column represents the number of men and women aged 15--49 years ($N^{T}$) who resided in the surveillance area. Also shown are the HIV-positive and HIV-negative prevalences (numerators and denominators not shown) and the expected number of HIV-negative and HIV-positive participants. Among men, the absolute HIV incidence rate declined from 2.6 to 1.1 events per 100 person-years between 2012 and 2017. HIV incidence declines occurred 2 year later among women, falling from 4.9 to 3.1 events per 100 person-years between 2014 and 2017. Trends in the absolute HIV incidence rate by men and women are shown in Panel A of [Figure 1](#dyz269-F1){ref-type="fig"}. Among men, there was a 62% reduction in the expected number of new HIV infections between 2012 ($I_{1} = ~$657 infections) and 2017 ($I_{2} =$251 infections). Among women, the expected number of new HIV infections increased by 8% between 2005 and 2013, before falling by 34% between 2014 ($I_{1} = ~$1146 infections) and 2017 ($I_{2} = ~$758 infections).

![Temporal trends in the HIV incidence rate (Panel A), all-cause HIV-positive mortality rate (Panel B), incidence-mortality ratio (Panel C) and HIV prevalence (Panel D) by sex in the Africa Health Research Institute surveillance area (2005--17). Panel E shows the (opposite-sex) female-incidence/male-prevalence (circle and solid line) and the male-incidence/female-prevalence (triangle and dashed line) ratios.](dyz269f1){#dyz269-F1}

###### 

Summary of the epidemic metrics by men and women in the Africa Health Research Institute surveillance area, 2005--17

              HIV survey[^a^](#tblfn4){ref-type="table-fn"}   Incidence cohort[^b^](#tblfn5){ref-type="table-fn"}   Mortality cohort[^c^](#tblfn6){ref-type="table-fn"}                                                                             
  ----------- ----------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -------- -------- ---------- ------ ------ ---------- ------ ----- ------ -------
  **Men**                                                                                                                                                                                                                                           
  2005        27 551                                          86.6                                                  13.4                                                  23 859   3691     67/3047    2.20   525    60/791     7.59   280   1.87   0.057
  2006        27 280                                          86.9                                                  13.1                                                  23 706   3573     78/3347    2.31   548    51/969     5.26   188   2.91   0.061
  2007        26 972                                          85.6                                                  14.4                                                  23 088   3883     81/3412    2.35   543    69/1041    6.63   257   2.11   0.055
  2008        27 769                                          86.1                                                  13.9                                                  23 909   3859     83/3445    2.40   575    50/1151    4.35   168   3.43   0.054
  2009        28 461                                          83.5                                                  16.5                                                  23 764   4696     83/3259    2.55   606    52/1245    4.18   196   3.09   0.051
  2010        30 750                                          83.8                                                  16.2                                                  25 768   4981     83/3167    2.60   671    51/1316    3.88   193   3.48   0.049
  2011        30 942                                          84.0                                                  16.0                                                  25 991   4950     75/3029    2.45   637    48/1473    3.26   161   3.95   0.046
  2012        30 234                                          83.4                                                  16.6                                                  25 215   5018     75/2848    2.60   657    54/1521    3.55   178   3.69   0.048
  2013        30 757                                          81.8                                                  18.2                                                  25 159   5597     68/2862    2.35   592    42/1614    2.60   146   4.06   0.039
  2014        30 046                                          80.1                                                  19.9                                                  24 066   5979     55/2889    1.89   456    38/1689    2.25   134   3.39   0.028
  2015        31 605                                          81.8                                                  18.2                                                  25 852   5752     41/2822    1.43   370    46/1809    2.54   146   2.53   0.021
  2016        31 574                                          81.0                                                  19.0                                                  25 574   5999     31/2474    1.25   320    55/1918    2.87   172   1.86   0.017
  2017        29 596                                          81.0                                                  19.0                                                  23 972   5623     20/1878    1.05   251    28/1965    1.42   80    3.14   0.015
  **Women**                                                                                                                                                                                                                                         
  2005        36 248                                          74.6                                                  25.4                                                  27 041   9206     186/4568   4.07   1101   110/2312   4.76   438   2.51   0.300
  2006        36 002                                          75.0                                                  25.0                                                  27 001   9000     223/5010   4.45   1202   98/2765    3.54   319   3.77   0.340
  2007        36 183                                          72.7                                                  27.3                                                  26 305   9877     232/5079   4.56   1201   105/3056   3.44   339   3.54   0.310
  2008        36 814                                          71.3                                                  28.7                                                  26 248   10 565   231/5050   4.58   1201   101/3438   2.94   310   3.87   0.310
  2009        37 962                                          68.6                                                  31.4                                                  26 041   11 920   223/4818   4.62   1203   84/3695    2.27   271   4.44   0.260
  2010        39 978                                          65.5                                                  34.5                                                  26 185   13 792   221/4685   4.72   1236   75/3987    1.88   259   4.76   0.250
  2011        39 364                                          65.0                                                  35.0                                                  25 586   13 777   210/4569   4.58   1172   73/4494    1.62   224   5.24   0.240
  2012        38 111                                          64.0                                                  36.0                                                  24 391   13 719   214/4321   4.94   1205   65/4642    1.40   192   6.27   0.240
  2013        39 820                                          62.0                                                  38.0                                                  24 688   15 131   211/4358   4.82   1191   61/4934    1.24   187   6.37   0.210
  2014        39 646                                          59.4                                                  40.6                                                  23 549   16 096   211/4333   4.87   1147   58/5188    1.12   180   6.37   0.190
  2015        42 038                                          58.4                                                  41.6                                                  24 550   17 487   183/4232   4.31   1059   61/5541    1.10   193   5.50   0.180
  2016        43 605                                          57.9                                                  42.1                                                  25 247   18 357   143/3786   3.77   951    72/5998    1.20   220   4.32   0.160
  2017        41 416                                          59.5                                                  40.5                                                  24 642   16 773   93/3006    3.08   758    65/6198    1.05   176   4.31   0.130

$N^{T}$ gives the total number of participants who resided for \>50% of the year in the surveillance area (irrespective of consent to HIV testing). HIV^+^ Prev. and HIV^−^ Prev. represent the HIV-positive and HIV-negative prevalence, respectively. The expected number of HIV-negatives (column 5) is obtained by multiplying $N^{T}$(column 2) by the HIV-negative prevalence (column 3). The expected number of HIV-positives (column 6) is obtained by multiplying $N^{T}$ (column 2) by the HIV-positive prevalence (column 4).

Shows the number of observed HIV infections (HIV Inf.) and person-years of observation (column 7). The HIV incidence (HIV Inc.) rate is per 100 person-years (column 8). The expected number of new HIV infections (column 9) is obtained by multiplying the expected number of HIV-negatives (column 5) by the HIV incidence rate/100 (column 8).

Shows the number of observed deaths among HIV-positive persons and the person-years of observation (column 10). The HIV-related mortality rate is per 100 person-years (column 11). The expected number of HIV-related deaths (column 12) is obtained by multiplying the expected number of HIV-positives (column 6) by the HIV-mortality rate/100 (column 11).

The incidence-mortality ratio (IMR, column 13) is obtained by dividing the expected number of new HIV infections (column 9) by the expected number of HIV-related deaths (column 12).

The incidence-prevalence ratio (IPR, column 14) is obtained by dividing the expected number of new HIV infected participants (column 9, e.g. males) by the expected number of opposite-sex HIV-positive participants (column 6, e.g. females).

The number of HIV-related deaths, the person-years contributed by HIV-positive participants and the expected number of HIV-related deaths are shown in [Table 2](#dyz269-T2){ref-type="table"}. Panel B in [Figure 1](#dyz269-F1){ref-type="fig"} shows significant reductions in the all-cause mortality rate among HIV-positive men and women. Among HIV-positive women, the all-cause mortality rate dropped from 4.8 to 1.1 deaths per 100 person-years between 2005 and 2017 ('Mort. Rate' in [Table 2](#dyz269-T2){ref-type="table"}). Nevertheless, the female incidence-mortality ratio was high, rising to 6.4 in 2013 before falling to 4.3 in 2017 ('IMR' in [Table 2](#dyz269-T2){ref-type="table"} and Panel C of [Figure 1](#dyz269-F1){ref-type="fig"}). The incidence-mortality ratio was lower among men, which peaked at 4.1 in 2013 and closed at 3.1 in 2017.

Consistent with a declining all-cause AIDS mortality rate, we observed a steady increase in the prevalence of HIV among men and women (Panel D of [Figure 1](#dyz269-F1){ref-type="fig"}). Between 2012 and 2017, the female-incidence/male-prevalence ratio declined from 0.24 to 0.13 and the male-incidence/female-prevalence ratio, which was comparatively lower, declined from 0.05 to 0.02 ('IPR' in [Table 2](#dyz269-T2){ref-type="table"}). These opposite-sex incidence-prevalence ratios confirm the disproportionate burden of HIV among women relative to men when compared with their same-sex versions, as shown in [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online. Despite a steady decline in the overall incidence-prevalence ratio, it remained above the epidemic threshold of 0.03, reaching 0.08 in 2017 (Panel E of [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} and 'IMR' in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Spatial estimates of the incidence rate, the incidence-mortality ratio and the incidence-prevalence ratio varied substantially over time. Among women, less than 5% of the surveillance area had an incidence-mortality ratio \<1 in 2014, which increased to 10% in 2017 ([Figure 2](#dyz269-F2){ref-type="fig"}, Row 1). Among men, an incidence-mortality ratio \<1 was prevalent in 30% of the surveillance area in 2014, which increased to 47% in 2017 ([Figure 3](#dyz269-F3){ref-type="fig"}, Row 1). Increases in areas with an incidence-mortality ratio \<1 correspond with large temporal declines in the HIV incidence rate during this period, as shown in [Figures 2](#dyz269-F2){ref-type="fig"} and [3](#dyz269-F3){ref-type="fig"} (Row 2). The prevalence of areas with a male-incidence/female-prevalence ratio \<0.03 increased from 16% in 2011 to 43% in 2014 and to 62% in 2017. The female-incidence/male-prevalence ratio was relatively flat between 2005 and 2014, with less than 1% of the area achieving the 0.03 threshold; thereafter, areas with a female-incidence/male-prevalence ratio \<0.03 increased to 8% in 2017. The incidence-mortality and incidence-prevalence ratios showed an emerging male microepidemic in the western part of the surveillance area ([Figures 3](#dyz269-F3){ref-type="fig"} and [4](#dyz269-F4){ref-type="fig"}).

![Spatial representation of the incidence-mortality ratio, expected number of new HIV infections (per 1 km by 1 km) and expected number of AIDS-related deaths (per 1 km by 1 km) among women for 2005, 2011, 2014 and 2017.](dyz269f2){#dyz269-F2}

![Spatial representation of the incidence-mortality ratio, expected number of new HIV infections (per 1 km by 1 km) and expected number of AIDS-related deaths (per 1 km by 1 km) among men for 2005, 2011, 2014 and 2017.](dyz269f3){#dyz269-F3}

![Spatial representation of the female-incidence/male-prevalence ratio (top row) and male-incidence/female-prevalence ratio (bottom row) for 2005, 2011, 2014 and 2017.](dyz269f4){#dyz269-F4}

Discussion
==========

South Africa is at the epicentre of the HIV pandemic, with the highest number of new infections and the most people living with AIDS.[@dyz269-B4] Over the past decade, the country has received substantial investment to scale up the world's largest HIV treatment programme.[@dyz269-B17]^,^[@dyz269-B27] Attention is now focused on interim progress to bring the HIV epidemic under control by 2030.[@dyz269-B28] One way to evaluate progress is to use single disease metrics that combine information on HIV-related mortality, HIV incidence and HIV prevalence. To this end, the UNAIDS has proposed the percentage reduction in incidence, the absolute incidence rate, the incidence-mortality ratio and the incidence-prevalence ratio, each having a specific target to mobilize efforts in the fight against HIV.[@dyz269-B2]

Our results show impressive progress toward HIV epidemic control. However, epidemic transition targets were not achieved during the observation period. The 62% reduction in the number of new HIV infections among men (between 2012 and 2017) and the 34% reduction among women (between 2014 and 2017) are off track for the 75% target set by the UNAIDS for 2020. During these two time periods, respectively, we also observed significant declines in the absolute incidence rate: from 2.6 to 1.1 events per 100 person-years among men and from 4.9 to 3.1 events per 100 person-years among women. The decline in HIV incidence is consistent with the scale up of voluntary medical male circumcision (VMMC) and ART services in the surveillance area between 2009 and 2011.[@dyz269-B6] Nevertheless, the overall HIV incidence rate is currently well above the recommended target of 1 infection per 1000 person-years.

In line with the percentage and absolute incidence reductions, we also observed declines in the incidence-mortality ratio. The male incidence-mortality ratio peaked at 4.1 in 2013 before dropping to 3.1 in 2017 (a 24% reduction) and the female incidence-mortality ratio climbed to as high as 6.4 in 2013 before dropping to 4.3 in 2017 (a 33% reduction). Although these results indicate interim progress, the incidence-mortality ratios are high and above the threshold of 1. The failure to achieve epidemic control is due to a persistently high HIV incidence rate relative to a rapidly declining all-cause mortality rate among HIV-positive participants---a decline attributed to the survival benefits of ART.[@dyz269-B29]^,^[@dyz269-B30] Because of the declining HIV-positive mortality, and therefore a steady increase in HIV prevalence, we observed reductions in the incidence-prevalence ratios over the observation period. Specifically, between 2012 and 2017, the male-incidence/female-prevalence ratio declined from 0.05 to 0.02. Compared with men, however, the female-incidence/male-prevalence ratio was markedly higher and fell from 0.24 to 0.13 during the same period. This result, when coupled with the higher HIV incidence, incidence-mortality ratio and HIV prevalence among women, confirms the disproportionate burden of HIV being experienced by women relative to men in sub-Saharan Africa.[@dyz269-B6]^,^[@dyz269-B14]^,^[@dyz269-B31]

We observed substantial heterogeneity in the epidemic control metrics over place and time. Areas having an incidence-prevalence ratio \<0.03 increased from 43% to 62% among men and from 1% to 8% among women between 2014 and 2017. Among men, an incidence-mortality ratio \<1 was prevalent in 30% of the surveillance area in 2014, which increased to 47% in 2017. Both metrics also revealed an emerging male microepidemic in the west of the surveillance area, coinciding with the scale up of mining and other industrial activities.[@dyz269-B32] The epidemic was also concentrated in the south-east of the surveillance area, which borders a national highway and includes the KwaMsane township. Previous studies have reported high rates of HIV infection in this area.[@dyz269-B33] Using the epidemic metrics, our study highlights two hyperendemic areas that could benefit from targeted HIV prevention services.

Our study has several potential limitations. First, cohort study designs are recognized as the gold standard for incidence rate estimation,[@dyz269-B34] but it is often a challenge to maintain consistent participation rates over time.[@dyz269-B35] In the AHRI surveillance area, the cumulative testing rate was relatively high, with the percentage of participants with at least one HIV test increasing from 42% to 79% over the observation period. Importantly, 71% of HIV-negative participants who were eligible for entry in the incidence cohort contributed person-time to the current analysis. In a recent study, we rigorously show that reductions in HIV incidence were robust to participant selection, missed tests and drop-out.[@dyz269-B6] Second, it is possible that the large reductions in HIV incidence and HIV-related mortality could be explained by unobserved secular trends. However, population-based studies undertaken in Uganda, Kenya and South Africa have reported similar declines in HIV incidence following increased VMMC and ART coverage between 2011 and 2016.[@dyz269-B5]^,^[@dyz269-B7]^,^[@dyz269-B8] We have recently shown that the declines in the male and female HIV incidence rates in the surveillance area are consistent with the introduction of a local VMMC programme and opposite-sex ART coverage surpassing 35%.[@dyz269-B6] Given mounting evidence, the scale-up of HIV prevention services is likely the key driver of progress toward epidemic control in sub-Saharan Africa.[@dyz269-B14]

The major strength of this study is our use of real-world data, collected from an entire population for over a decade, to estimate the four epidemic control metrics. This was made possible by AHRI's comprehensive demographic surveillance system, in which fieldworkers have visited households, recorded deaths through verbal autopsies and tested participants for HIV on an annual basis since 2005. We leveraged these data to calculate key indicators such as the HIV prevalence, HIV incidence rate and the HIV-related mortality rate, which are needed for the incidence-mortality and incidence-prevalence ratios. Our empirically based results are an advance over recent work that has used mathematical models to derive estimates of the four metrics.[@dyz269-B14]^,^[@dyz269-B15] As far as we know, no other study has presented, in the same analysis, empirical estimates of the four metrics and shown how they have varied over place and time.

In summary, there has been impressive progress toward HIV epidemic control in a hyperendemic South African setting. Nevertheless, expanded and optimized HIV prevention services are needed to reach key UNAIDS milestones. Our results, which show heterogeneity in the metrics over place and time, highlight areas that could benefit from these prevention services.
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